Agenda
Applications for consideration at this meeting
- 1573 Reproductive carrier screening for fragile X syndrome, spinal muscular atrophy and cystic fibrosis
- 1582 Detection of Aquaporin-4 (AQP4) antibodies in serum of cerebrospinal fluid for diagnosis of Neuromyelitis optica (NMO)
- 1585 Genetic testing for the diagnosis of early-onset or familial neuromuscular disorders
- 1595 Closed loop upper airway stimulation for moderate to severe obstructive sleep apnoea, in patients who have failed or are intolerant to, continuous positive airway pressure (CPAP) therapy
- 1597 Cryoablation for biopsy-confirmed renal cell carcinoma (RCC) ≤4cm in patients not suitable for partial nephrectomy
- 1598 Genetic testing for diagnosis of inheritable cardiac rhythm disorders
- 1599 Genomic testing for the diagnosis of heritable cardiomyopathies
- 1600 Genetic testing for heritable kidney disease (other than Alport syndrome)
- 1602 Testing for neurotrophic tyrosine receptor kinase (NTRK) gene fusion status, in patients with locally advanced or metastatic solid tumours, to determine eligibility for larotrectinib
- 1603 Transcatheter aortic valve implantation (TAVI) via transfemoral delivery, using the SAPIEN 3 balloon-expandable valve (BEV) system, for patients at intermediate risk for surgery
- 1604 PIK3CA mutation testing for postmenopausal women or men with advanced breast cancer who have progressed during or following treatment with an aromatase inhibitor
- 1605 Transcatheter delivery of a dual-filter cerebral embolic protection system during transcatheter aortic valve implantation
Related information
Committee: